Clinical Trial Update: Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imaging of HER2 expression in primary breast cancer using the radiotracer ZHER2:4107; enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ZHER2:4107

Snippet

Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences | Conditions: Primary Breast Cancer | Phase 2 | Status: ENROLLING_BY_INVITATION